Tenaya Therapeutics, Inc.
TNYA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.39
KIRA · Stoqly’s AI analyst, in plain words
- Tenaya Therapeutics, Inc. lost $90.6M in fiscal 2025.
- Free cash flow was −$68.9M in fiscal 2025, — of revenue.
Market cap
$84.6M
P/E
—
Revenue
—
Net income
−$90.6M
Free cash flow
−$68.9M
Operating margin
—
Tenaya Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$90.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tenaya Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Legal name
- Tenaya Therapeutics, Inc.
- CIK
- 0001858848
Tenaya Therapeutics, Inc. · TNYA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$72.7M | −$124M | −$124M | −$111M | −$90.6M |
| Diluted EPS | −$4.10 | −$2.76 | −$1.68 | −$1.31 | −$0.59 |
| Cash | |||||
| Cash from operations | −$60.8M | −$104M | −$102M | −$90.5M | −$68.3M |
| Capital expenditure | $25.1M | $20.6M | $1.2M | $1.0M | $0.6M |
| Free cash flow | −$85.9M | −$125M | −$103M | −$91.5M | −$68.9M |
| Share buybacks | $0.0M | — | — | — | — |
| Share count change | 1,724.3% | 152.8% | 64.6% | 15.0% | 80.3% |
| Debt and strength | |||||
| Cash and short-term investments | $251M | $187M | $105M | $61.4M | $101M |
| Shareholders' equity | $279M | $243M | $139M | $92.9M | $123M |
| Current ratio | 11.7x | 8.0x | 4.9x | 4.2x | 6.8x |
| Returns and quality | |||||
| Return on equity | −73.7% | −47.4% | −64.8% | −95.7% | −83.8% |
| Return on tangible equity | −26.1% | −50.8% | −89.0% | −119.7% | −73.5% |
| Altman Z'' | 9.9 | 4.9 | −4.8 | −14.1 | −8.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$6.0M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tenaya Therapeutics, Inc. · TNYA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.39 a share, the company is worth $84.6M.
Source: SEC EDGAR XBRL filings (CIK 0001858848). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.